Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2025.

“The first quarter of 2025 was marked by significant progress across both our pipeline and strategic partnerships,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “Sanofi’s €15 million equity investment reflects our shared conviction in the potential of our pipeline and the strength of our partnership. With the initiation of the Phase 1 study for our Nectin-4 ADC, IPH4502 and presentation at AACR and the FDA’s Breakthrough Therapy Designation for lacutamab with upcoming ASCO presentations, we are well-positioned to deliver innovative therapies to patients. Our strengthened financial position provides a cash runway into mid 2026.”

Webcast and conference call will be held today at 2:00pm CEST (8:00am ET) Access to live webcast: https://events.q4inc.com/attendee/806006771   Participants may also join via telephone using the registration link below: https://registrations.events/direct/Q4I227404000000000000   This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event.

1 Including short term investments (€13.6m) and non-current financial instruments (€10.4m).

Pipeline highlights

ANKET (Antibody-based NK cell Engager Therapeutics):

ANKET is Innate’s proprietary platform for developing next-generation, multi-specific NK cell engagers to treat certain types of cancer.

IPH6501 (ANKET anti-CD20 with IL-2V, proprietary)

The Phase 1/2 clinical trial evaluating IPH6501 in B-cell Non-Hodgkin’s lymphoma (B-NHL) is ongoing. The study is planned to enroll up to 184 patients. Clinical sites are open in the US, Australia and France and the first safety and preliminary activity data are expected in late 2025.

IPH6101 (ANKET anti-CD123)

In alignment with both companies' current strategic priorities, Sanofi and Innate agreed to terminate the 2016 Research Collaboration and Licence Agreement (the “2016 Agreement”) as it relates to SAR’579/IPH6101 (CD123 ANKET); Innate will regain its rights on SAR’579/IPH6101 (CD123 ANKET).